CD22 - CD22 molecule Gene

Also Known as SIGLEC2; SIGLEC-2

Species: Homo sapiens

Gene Type: protein coding

Gene ID: 933

About CD22

Cytogenetic location: 19q13.12 Genomic coordinates (GRCh38): 19:35,329,187-35,347,361 (from NCBI)

This gene has 34 transcripts (splice variants), 158 orthologues and 16 paralogues. Biased expression in lymph node (RPKM 101.0), ovary (RPKM 64.7) and 2 other tissues.

Summary

Predicted to enable CD4 receptor binding activity; protein Phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022]

CD22 Products (5)

mRNA	Protein	Name
NM_001185099.2	NP_001172028.1	B-cell receptor CD22 isoform 2 precursor
NM_001185100.2	NP_001172029.1	B-cell receptor CD22 isoform 3 precursor
NM_001185101.2	NP_001172030.1	B-cell receptor CD22 isoform 4 precursor
NM_001278417.2	NP_001265346.1	B-cell receptor CD22 isoform 5
NM_001771.4	NP_001762.2	B-cell receptor CD22 isoform 1 precursor

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	References	Source
enables protein binding	IPI IPI: Inferred from physical interaction	8627166	GOA

Biological Process GO Annotation	Evidence	References	Source
involved in B cell activation	IDA IDA: Inferred from direct assay	26017478	GOA
involved in negative regulation of B cell receptor signaling pathway	IDA IDA: Inferred from direct assay	26017478	GOA
involved in negative regulation of B cell receptor signaling pathway	IMP IMP: Inferred from mutant phenotype	24169826	GOA
involved in regulation of endocytosis	IDA IDA: Inferred from direct assay	17562860	GOA

Cellular Component GO Annotation	Evidence	References	Source
located in early endosome	IDA IDA: Inferred from direct assay	17562860	GOA
located in recycling endosome	IDA IDA: Inferred from direct assay	17562860	GOA

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

CD22 Protein Structure

C2-set_2

Ig_2

0
200
400
600
800
847 a.a.

Protein Preferred Names	Protein Names
B-cell receptor CD22	B-lymphocyte cell adhesion molecule

CD22 Protein-protein interaction Information

Type	Protein Name	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	References
Intra	CD22	P20273	PTPN6	Homo sapiens	P29350	CoIP	8627166
Intra	CD22	P20273	SYK	Homo sapiens	P43405	CoIP	8627166
Intra	CD22	P20273	SYK	Homo sapiens	P43405	CoIP	8647200
Intra	CD22	P20273	PLCG1	Homo sapiens	P19174	CoIP	8627166
Intra	CD22	P20273	LYN	Homo sapiens	P07948	CoIP	8647200

Cross: Cross-species interaction Intra: Intraspecies interaction

Recombinant CD22 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P70560	Siglec-2/CD22 Protein, Human (HEK293, Fc)	P20273 (D20-R687)	≥ 95%, as determined by reducing SDS-PAGE.
HY-P72019	Siglec-2/CD22 Protein, Human (HEK293, His)	P20273 (R20-R687)	≥ 90%, as determined by reducing SDS-PAGE.
HY-P72351	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi)	P20273 (D20-R687)	≥ 95%, as determined by reducing SDS-PAGE.
HY-P73648	Siglec-2/CD22 Protein, Human (512a.a, HEK293, His)	P20273 (W176-R687)	≥ 90%, as determined by reducing SDS-PAGE.
HY-P77537	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His)	P20273 (D20-R687)	≥ 95%, as determined by reducing SDS-PAGE.
HY-P77539	Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His)	P20273 (W176-R687)	≥ 95%, as determined by reducing SDS-PAGE.
HY-P78541	FITC-Labeled Siglec-2/CD22 Protein, Human (HEK293, Fc)	P20273 (D20-R687)	≥ 95%, as determined by Bis-Tris PAGE.

CD22 Antibodies

Cat. No.	Product Name	Application	Reactivity
HY-P81522	CD22 Antibody (YA1267)	IHC-P	Human
HY-P81522A	CD22 Antibody (YA1267)(PBS only)	IHC-P	Human
HY-P84169	CD22 Antibody (YA3866)	WB, IHC-P, ICC/IF, FC, ELISA	Human
HY-P84169A	CD22 Antibody (YA3866)(PBS only)	WB, IHC-P, ICC/IF, FC, ELISA	Human
HY-P84975	CD22 Antibody (YA4667)	FC, ELISA	Human

Related Diseases

Diseases	Alias
Refractory Hairy Cell Leukemia
Refractory Hematologic Cancer	Refractory Hematologic Malignancy
B-Cell Prolymphocytic Leukemia	B Cell Prolymphocytic Leukemia Prolymphocytic Leukemia, B-Cell Type B-Pll Doid:0081041 Leukemia, Prolymphocytic, B-Cell Pll- [Prolymphocytic Leukaemia] Prolymphocytic Leukaemia Prolymphocytic Leukaemia Of B-Cell Type Without Mention Of Remission
Early Yaws	Initial Lesions Of Yaws Bone And Joint Lesions Due To Yaws Bone And Joint Yaws Lesion Chancre Of Yaws Frambesia, Initial Or Primary Initial Frambesial Ulcer Primary Frambesia Initial Lesion Of Yaws
Hairy Cell Leukemia	Hcl-V Hairy Cell Leukemia Variant Hairy Cell Leukaemia Variant Hcl Leukemic Reticuloendotheliosis Leukemic Reticuloendotheliosis Variant Prolymphocytic Variant Of Hcl Prolymphocytic Variant Of Hairy Cell Leukemia Leukemia Hairy Cell Leukemia, Hairy Cell Leukaemic Reticuloendotheliosis Lre - [Leukemic Reticuloendotheliosis] Hairy-Cell Leukaemia, Nos Hcl - [Hairy Cell Leukaemia] Hairy-Cell Leukaemia Without Mention Of Remission
Acute Leukemia	Stem Cell Leukaemia Stem Cell Leukemia Acute Leukemias Acute Undifferentiated Leukemia Undifferentiated Leukemia Acute Leukaemia Of Unspecified Cell Type Without Mention Of Remission Blast Cell Leukaemia Blast Leukaemia Blastic Leukaemia Undifferentiated Leukaemia
Eye Lymphoma	Malignant Lymphoma Of Eye Lymphoma Of Eye
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Adult Lymphoma
Hyperglobulinemic Purpura	Purpura, Hyperglobulinemic
Spleen Cancer	Spleen Neoplasm Splenic Neoplasm Splenic Neoplasms Malignant Splenic Tumor Malignant Tumour Of Spleen Tumor Of Spleen Malignant Neoplasm Of Spleen
Splenic Marginal Zone Lymphoma	Smzl Splenic Marginal Zone B-Cell Lymphoma
B-Cell Lymphoma	Lymphoma, B-Cell B-Cell Lymphomas B-Cell Lymphocytic Neoplasm Lymphoma B-Cell B-Cell Lymphoma Nos
Leukemia, Acute Lymphoblastic	Acute Lymphoblastic Leukemia ALL Acute Lymphocytic Leukemia Leukemia, Acute Lymphocytic, Susceptibility To, 1 Acute Lymphoblastic Leukaemia Precursor Lymphoblastic Lymphoma/Leukemia Precursor Lymphoid Neoplasm Leukemia, Acute Lymphoblastic, Susceptibility To B-Cell Acute Lymphoblastic Leukemia Leukemia, Acute Lymphocytic 1 Acute Lymphocytic Leukaemia Acute Lymphoblastic Leukemia/Lymphoma All1 Childhood Acute Lymphoblastic Leukemia Leukemia Acute Lymphoblastic 1 Leukemia Acute Lymphoblastic B-Hyperdiploid Leukemia Acute Lymphocytic Leukemia Acute Lymphocytic 1 Leukemia B-Cell Acute Lymphoblastic Leukemia T-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic, 3 ALL3 Lymphoblastic Leukemia Acute Leukemia, Acute, Lymphoblastic Precursor Cell Lymphoblastic Leukemia Lymphoma Leukemia, Lymphocytic, Acute, L1 Leukemia, Acute Lymphoblastic, Susceptibility To, 3
Intraocular Lymphoma	Primary Intraocular Lymphoma Piol Primary Intraocular Non-Hodgkin Lymphoma Primary Intraocular Non-Hodgkin Malignant Lymphoma
B-Cell Adult Acute Lymphocytic Leukemia	Adult B Acute Lymphoblastic Leukemia Adult B Acute Lymphoblastic Leukaemia Adult B-Cell Acute Lymphoblastic Leukaemia Adult B-Cell Acute Lymphoblastic Leukemia Adult B-Cell Lymphocytic Leukaemia Adult B-Cell Lymphocytic Leukemia Adult B-Lymphoblastic Leukaemia Adult B-Lymphoblastic Leukemia B-Cell Adult Acute Lymphocytic Leukaemia B-Cell Adult Acute Lymphoblastic Leukemia
Lymphoplasmacytic Lymphoma	Waldenstrom Macroglobulinemia Malignant Lymphoma - Lymphoplasmacytic Waldenström Macroglobulinaemia Waldenström Macroglobulinaemia Without Mention Of Remission Idiopathic Macroglobulinaemia Primary Macroglobulinaemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Cll/Sll B-Cell Lymphocytic Leukemia/Small Lymphocytic Lymphoma Icdo:9823/3 Chronic Lymphocytic Leukaemia Of B-Cell Type Without Mention Of Remission Small Cell B-Cell Lymphoma
Capillary Disease	Disease Of Capillaries
Composite Lymphoma	Composite Hodgkin And Non-Hodgkin Lymphoma
Childhood Lymphoma	Pediatric Lymphoma
Retina Lymphoma	Lymphoma Of Retina Retinal Lymphoma
Capillary Leak Syndrome	Systemic Capillary Leak Syndrome Clarkson Disease Capillary Leak Syndrome With Monoclonal Gammopathy Scls Periodic Systemic Capillary Leak Syndrome Capillary Hyperpermeability Syndrome Idiopathic Capillary Leak Syndrome
Hepatic Veno-Occlusive Disease	Veno-Occlusive Disease Sinusoidal Obstruction Syndrome Hepatic Venoocclusive Disease Venoocclusive Disease Hepatic Vein Thrombosis Budd-Chiari Syndrome Hepatic Vein Occlusion Veno-Occlusive Disease Of The Liver
Intellectual Developmental Disorder, Autosomal Dominant 4	MRD4 Autosomal Dominant Non-Syndromic Intellectual Disability 4 Mental Retardation, Autosomal Dominant 4 Autosomal Dominant Intellectual Developmental Disorder 4
Adult Acute Lymphocytic Leukemia	Adult Acute Lymphoid Leukemia Adult All
B-Lymphoblastic Leukemia/Lymphoma	B Lymphoblastic Leukemia/Lymphoma B-All Precursor B Lymphoblastic Lymphoma/Leukemia C-All Lymphoblastic Lymphoma, Nos Common Precursor B All Lymphoblastic B-Cell Lymphoma Pro-B All B-Precursor Lymphoma Lbl - [Lymphoblastic Lymphoma]
Acute Biphenotypic Leukemia	Mixed Phenotype Acute Leukemia Acute Leukemia Of Ambiguous Lineage Acute Undifferentiated Leukemia Acute Leukemia Of Indeterminate Lineage Hybrid Acute Leukemia Mixed Lineage Acute Leukemia All With Myeloid Markers Aml With Lymphoid Markers Acute Leukemia Of Undetermined Lineage Bal Biphenotypic Acute Leukemia Undifferentiated Acute Leukemia Mpal Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 Leukemia, Biphenotypic, Acute
Marginal Zone B-Cell Lymphoma	Marginal Zone Lymphoma Mzl Mucosa-Associated Lymphoid Tissue Lymphoma
Puerperal Pulmonary Embolism	Obstetric Pulmonary Embolism
Autoimmune Disease	Autoimmune Diseases Autoimmune Hypersensitivity Disease Hypersensitivity Reaction Type Ii Disease Type Ii Hypersensitivity Reaction Disease
Richter'S Syndrome	Richter Syndrome Richter Transformation
Mantle Cell Lymphoma	Lymphoma, Mantle Cell Lcm Mcl Mantle Zone Lymphoma Lymphoma Mantle-Cell Lymphoma, Mantle-Cell Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse Malignant Lymphoma - Lymphocytic, Intermediate Differentiation Diffuse Small Cleaved-Cell Lymphoma Diffuse Small Cleaved Cell Malignant Lymphoma Small Cleaved Cell Non-Hodgkin Lymphoma Diffuse Non-Hodgkin Small Cleaved Cell Lymphoma Malignant Lymphomatous Polyposis Malignant Small Cell, Noncleaved, Diffuse Lymphoma Malignant Undifferentiated Cell, Non-Burkitt Lymphoma Cleaved Cell Lymphoma Small Cell Mantle Cell Lymphoma Small Cleaved Cell Malignant Lymphoma
Systemic Lupus Erythematosus	Lupus Nephritis SLE Disseminated Lupus Erythematosus Systemic Lupus Erythematosus, Susceptibility To Lupus Erythematosus, Systemic Lupus Nephritis, Susceptibility To Libman-Sacks Disease Systemic Lupus Erythematosus Susceptibility To Sle - Lupus Erythematosus, Systemic Le Syndrome Lupus Lupus Erythematosus Systemic Lupus Erythematosus, Systemic, Susceptibility To Lupus Vulgaris Lupus Erythematosus, Discoid Lupus Erythematosus Systemic Lupus Erythematosus Nos Sle - [Systemic Lupus Erythematosus]
Lung Cancer	Lung Carcinoma Non-Small Cell Lung Carcinoma Lung Cancer, Susceptibility To Lung Cancer, Protection Against Adenocarcinoma Of Lung, Somatic Adenocarcinoma Of Lung, Response To Tyrosine Kinase Inhibitor In Nonsmall Cell Lung Cancer Lung Neoplasm Carcinoma Of Lung Lung Non-Small Cell Carcinoma Non-Small Cell Lung Cancer Nsclc Lung Neoplasms Malignant Neoplasm Of Lung Alveolar Cell Carcinoma Nonsmall Cell Lung Cancer, Somatic Nonsmall Cell Lung Cancer, Response To Tyrosine Kinase Inhibitor In Nonsmall Cell Lung Cancer, Susceptibility To Lung Cancer, Somatic Lung Cancer, Resistance To Cancer Of Lung Cancer Of Bronchus Cancer Of The Lung Lung Malignancies Lung Malignant Tumors Malignant Lung Tumor Malignant Tumor Of Lung Pulmonary Cancer Pulmonary Carcinoma Pulmonary Neoplasms Respiratory Carcinoma LNCR Adenocarcinoma Of Lung Neoplasm Of Lung Cancer Lung Carcinoma Non-Small Cell Lung Carcinoma, Non-Small-Cell Lung Lung Cancers Lung Carcinomas Cancer, Lung Cancer, Lung, Non-Small Cell Primary Malignant Neoplasm Of Lung Bronchioloalveolar Adenocarcinoma
Mature B-Cell Neoplasm	Mature B-Cell Lymphocytic Neoplasm Neoplasm Of Mature B-Cells Mature B-Cell Non-Hodgkin Neoplasm With Leukaemic Behaviour
Splenic Disease	Splenic Diseases Dyssplenism Spleen Disease Abnormality Of The Spleen Spleen Diseases
Refractory Plasma Cell Neoplasm
Lymphoma, Mucosa-Associated Lymphoid Type	Malt Lymphoma Gastric Lymphoma, Primary Lymphoma, Malt, Somatic Mucosa-Associated Lymphoid Tissue Lymphoma Extranodal Marginal Zone B-Cell Lymphoma MALTOMA Marginal Zone B-Cell Lymphoma Mucosa-Associated Lymphatic Tissue Lymphoma Primary Gastric Lymphoma Gastric Lymphoma Familial Primary Gastric Lymphoma
Complement Component 7 Deficiency	C7 Deficiency C7D
Renal Pelvis Transitional Cell Carcinoma	Urothelial Cell Carcinoma Of Renal Pelvis Renal Pelvis Urothelial Carcinoma Transitional Cell Carcinoma Of Renal Pelvis
Pancytopenia
Soft Palate Cancer	Malignant Tumor Of Soft Palate Malignant Tumor Of The Soft Palate Palate Cancer Soft Palate
Leukemia, Chronic Lymphocytic	Chronic Lymphocytic Leukemia B-Cell Chronic Lymphocytic Leukemia CLL B-Cell Chronic Lymphoid Leukemia Chronic Lymphatic Leukemia Chronic Lymphocytic Leukaemia Lymphoplasmacytic Leukemia Small Lymphocytic Lymphoma Leukemia, Chronic Lymphatic B-Cell Chronic Lymphocytic Leukaemia Chronic Lymphatic Leukaemia Lymphoplasmacytic Leukaemia B Cell Chronic Lymphocytic Leukemia Chronic B-Cell Lymphocytic Leukemia Leukemia, Lymphocytic, Chronic B-Cll Chronic Lymphoid Leukemia Leukemia Lymphocytic Chronic Lymphoma Small Lymphocytic Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin, Familial	Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin NHL Lymphoma, Non-Hodgkin, Somatic Lymphoma, Follicular, Somatic Familial Non-Hodgkin Lymphoma Lymphoma Non-Hodgkins Follicular Lymphoma, Somatic Lymphosarcoma Non-Hodgkins Lymphoma
Leukemia, Acute Myeloid	Acute Myeloid Leukemia Leukemia, Acute Myelogenous Acute Myelogenous Leukemia AML Leukemia, Acute Myeloid, Susceptibility To Acute Myeloblastic Leukemia Leukemia, Acute Myeloid, Reduced Survival In, Somatic Acute Myeloid Leukaemia Leukemia, Myelocytic, Acute Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome Secondary Aml Acute Myelocytic Leukemia Acute Myeloid Leukemia, Somatic Leukemia, Acute Myeloid, Somatic Myeloid Leukemia, Acute, M4/M4eo Subtype, Somatic Acute Myeloblastic Leukaemia Acute Myelogenous Leukaemia Aml - Acute Myeloid Leukemia Acute Myeloid Leukemia With Cebpa Somatic Mutations Aml With Cebpa Somatic Mutations Inherited Acute Myeloid Leukemia Familial Aml Inherited Aml Pure Familial Aml Pure Familial Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Aml And Myelodysplastic Syndrome Acute Myeloid Leukemia, Secondary Acute Non-Lymphoblastic Leukemia Acute Non-Lymphocytic Leukemia Acute Biphenotypic Leukemia Acute Undifferentiated Leukemia Acute Myeloblastic Leukaemia With Multilineage Dysplasia Acute Myeloid Leukaemia With Multilineage Dysplasia Without Mention Of Remission Acute Myeloid Leukaemia With Myelodysplasia-Related Features

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Approval
Clinical Phase
Pre-clinical Phase

Approval

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P9959	Inotuzumab ozogamicin	Inhibitor	99.7%	Unkown

Clinical Phase

Inhibitory Antibodies (5)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99264	Inotuzumab	Inhibitor	96.19	Phase 4
HY-P99289	Epratuzumab		99.53%	Phase 3
HY-P990781	Suciraslimab	Inhibitor	97.42%	Phase 3
HY-P99230	Pinatuzumab	Inhibitor	96.98%	Phase 2
HY-P990759	Rezetamig	Inhibitor	95.65%	Phase 1

Pre-clinical Phase

Bioactive Molecules (5)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-141602	Pinatuzumab vedotin	Inhibitor	/	Unkown
HY-146081	CD22 ligand-1		/	Unkown
HY-171172	GSC-718	Inhibitor	/	Unkown
HY-185659	6'-BPANeuGc	Ligand	/	Unkown
HY-P9959A	Inotuzumab ozogamicin (solution)	Inhibitor	/	Unkown

Inhibitory Antibodies (6)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P99034	Moxetumomab	Inhibitor	99.77%	Unkown
HY-P990283	Anti-Mouse CD22 Antibody (Cy34.1)	Inhibitor	99%	Unkown
HY-P990930	Mozistobart		99.21%	Unkown
HY-P991550	RFB4	Inhibitor	96.93%	Unkown
HY-P991906	TRPH-222 Antibody		/	Unkown
HY-P99264A	Inotuzumab (powder)	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Felis catus	CD22	VGNC	VGNC:60597
Macaca mulatta	CD22	VGNC	VGNC:70758
Mus musculus	CD22	MGD	MGI:88322
Bos taurus	CD22	VGNC	VGNC:27012
Canis familiaris	CD22	VGNC	VGNC:38939
Rattus norvegicus	CD22	RGD	RGD:1311610
Others	CD22	NCBI